Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current nonsteroidal anti-inflammatory drug applications for rheumatic diseases.

Primary care·1993
Same author

The pharmacological control of musculoskeletal pain.

Canadian journal of physiology and pharmacology·1991
Same author

Order out of chaos--the primary mission of the pyramid.

The Journal of rheumatology·1990
Same author

Concepts in pain control.

Seminars in arthritis and rheumatism·1989
Same author

The management of pain by pharmacological agents.

The Clinical journal of pain·1989
Same author

Current modalities in arthritic diseases.

The American journal of medicine·1987
Same journal

The Role of Telemedicine on Interhospital Transfer Outcomes : A Systematic Review.

Annals of internal medicine·2026
Same journal

Prolonged Short Sleep and Its Effect on Body Weight and Composition : A Pooled Analysis of Randomized Trials.

Annals of internal medicine·2026
Same journal

In AF, LAAC was noninferior to NOAC therapy for a composite efficacy outcome and reduced non-procedure-related bleeding at 3 y.

Annals of internal medicine·2026
Same journal

How AI is affecting medical journals.

Annals of internal medicine·2026
Same journal

In adults with COPD, the BLISS score predicted risk for acute respiratory hospital admission at 2 y.

Annals of internal medicine·2026
Same journal

In AF at risk for stroke and bleeding, LAAC was not noninferior to medical therapy for a composite of thromboembolic and safety events.

Annals of internal medicine·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study
10:10

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study

Published on: August 15, 2016

Ibuprofen.

T G Kantor

    Annals of Internal Medicine
    |December 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Ibuprofen, an anti-inflammatory drug, offers pain relief with fewer stomach issues than aspirin. It is effective for rheumatoid arthritis and osteoarthritis, inhibiting prostaglandin synthesis.

    More Related Videos

    Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
    13:38

    Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

    Published on: January 18, 2017

    Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
    08:56

    Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

    Published on: November 30, 2022

    Related Experiment Videos

    Last Updated: May 12, 2026

    Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study
    10:10

    Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study

    Published on: August 15, 2016

    Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
    13:38

    Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

    Published on: January 18, 2017

    Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
    08:56

    Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

    Published on: November 30, 2022

    Area of Science:

    • Pharmacology
    • Rheumatology

    Background:

    • Ibuprofen introduced in 1967 (UK) and 1974 (US) as a human anti-inflammatory agent.
    • Possesses anti-inflammatory properties comparable to aspirin but with improved gastric tolerability.
    • Chemically related to other propionic acid derivatives like fenoprofen and naproxen.

    Purpose of the Study:

    • To review the efficacy and properties of ibuprofen as an anti-inflammatory and analgesic drug.
    • To compare ibuprofen's effects and side effects to aspirin.
    • To assess ibuprofen's effectiveness in various inflammatory conditions.

    Main Methods:

    • Review of existing literature on ibuprofen's pharmacological effects.
    • Clinical data analysis regarding efficacy in inflammatory diseases.
    • Pharmacological mechanism investigation focusing on prostaglandin synthesis inhibition.

    Main Results:

    • Ibuprofen demonstrates definite anti-inflammatory and analgesic properties.
    • It exhibits a better gastrointestinal safety profile compared to aspirin.
    • Effective in rheumatoid arthritis and osteoarthritis; potentially effective in ankylosing spondylitis, gout, and Bartter's syndrome.
    • Inhibits prostaglandin synthesis, classifying it as a nonsteroidal anti-inflammatory drug (NSAID).

    Conclusions:

    • Ibuprofen is a valuable NSAID for managing inflammatory conditions like rheumatoid arthritis and osteoarthritis.
    • Its favorable side effect profile, particularly regarding gastric tolerance, enhances its therapeutic utility.
    • Further investigation may confirm its efficacy in other inflammatory and pain-related syndromes.